Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 15, 2011Nephrology Dialysis TransplantationOpen Access

CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

FGFrançois GlowackiInsermALArnaud LionetUniversité de LilleDBDavid BuobInserm

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Glowacki et al. (2011) studied this question.

synapsesocial.com/papers/6aa3cce3971540f143c7ff47https://doi.org/10.1093/ndt/gfr253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cytochrome P4503APolymorphisms and Immunosuppressive Drugs: An Update2007 · 92 citations
  2. 2A "Silent" Polymorphism in the <i>MDR</i> 1 Gene Changes Substrate Specificity2006 · 2,487 citations
  3. 3Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing2010 · 364 citations
  4. 4ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation2005 · 221 citations
  5. 5Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts2009 · 144 citations